The first domestic new crown oral medication will be delivered to Xinjiang in two batches

Pomegranate/Xinjiang Daily (Reporter Ren Chunxiang reported) On August 12, the reporter learned from the Drug Administration of the Autonomous Region that at 2 am on the same day, the first batch of domestic new crown oral medicine Azf fixed films have arrived in Xinjiang. The second batch is expected to arrive in the early morning of August 13.

The relevant person in charge of the Drug Administration of the Autonomous Region said that at present, the two batches of new crown oral medicines of Xinjiang can meet the current clinical drug needs, and drug prices are open and transparent.

Azf's fixed tablet is the first approved new crown pneumonia oral drug. In terms of suppressing the role of the new coronal virus, Azf will inhibit the activity of the new coronary virus. In terms of security, Azf's general tolerance is good, and the incidence of adverse events has no statistical differences with the placebo group, and the risk of the subject has not increased.

According to the price of medical insurance networks in various places, Azf's fixed price is priced at 270 yuan per bottle, 35 tablets per bottle, and 1 mg per piece. According to the "New Coronatte Pneumonic Pneumonia Diagnosis Plan (Ninth Edition)", Azf's fixed tablets are used to treat adult patients with COVID-19) for general new type of coronary virus pneumonia (COVID-19). The amount of usage is swallowed by the entire space, 5mg each time, once a day, the course of treatment is not more than 14 days.

It is reported that Azf's fixed tablet can be temporarily included in the scope of medical insurance payment. On August 9, the National Health and Health Commission issued a notice that Azf was included in the new type of coronary virus pneumonia diagnosis and treatment plan. Patients with insured patients could pay in accordance with regulations when using the drug.

- END -